Novo Nordisk shares drop after poor trial results for new obesity drug

Novo Nordisk shares drop after poor trial results for new obesity drug

Once-a-week injection achieved weight loss of 23%, which is lower than some existing treatments

Leave a Reply

Your email address will not be published. Required fields are marked *

Page Reader Press Enter to Read Page Content Out Loud Press Enter to Pause or Restart Reading Page Content Out Loud Press Enter to Stop Reading Page Content Out Loud Screen Reader Support
WordPress Cookie Plugin by Real Cookie Banner